Pfizer raised profit estimates for 2025 thanks to cost cuts, despite falling COVID product revenue and patent expirations.
Sanziana Georgescu
Economy
sursa foto: shutterstock.com
Always see our news on Google
Pfizer has announced a revised profit estimate for 2025, underpinned by a cost-cutting program, amid falling COVID product revenues and patent expirations. Shares rose 3.7% after the company reported a better-than-expected quarterly profit. However, Pfizer remains cautious, maintaining annual sales forecasts of between $61 billion and $64 billion, due to pandemic uncertainties and political pressure to cut drug prices.
Sources
Pfizer își majorează estimarea de profit pentru 2025, pe fondul reducerilor masive de costuri și al presiunilor politice din partea lui Trump
Pfizer își ridică prognoza de profit pentru 2025, mizând pe reduceri agresive de costuri și negocieri
Pfizer îşi majorează estimarea de profit pentru 2025, pe fondul reducerilor masive de costuri şi al presiunilor politice din partea lui Trump
Pfizer îşi majorează estimarea de profit pentru 2025, pe fondul reducerilor masive de costuri şi al presiunilor politice din partea lui Trump
Latest News
22:56
Petrișor Peiu announces that AUR will summon Alexandru Nazare to Parliament for explanations regarding the budget deficit and will submit a simple motion against him
22:47
Ilie Bolojan stated that there is no question of replacing him as leader of the PNL
22:28
Ilie Bolojan, warning for the Niculescu Government: PNL will penalize budgetary deviations
21:57
Alexandru Rogobete announces a national program to reduce hospital-acquired infections
21:23
Latvian forces alerted the population after an unidentified object entered national airspace near the borders with Russia and Belarus
See more news
NEWS ON THE SAME TOPICS
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
